CD274 and nonpapillary renal cell carcinoma: Currently, numerous promising immunotherapy drugs, including PD-1/PD-L1, interleukin-2 (IL-2), and interferon (IFN) blocking agents, have been approved for the treatment of ccRCC 3, and the overall therapeutic effect is satisfactory 4.